Free Trial

Vontobel Holding Ltd. Takes Position in Ultragenyx Pharmaceutical Inc. $RARE

Ultragenyx Pharmaceutical logo with Medical background

Key Points

  • Vontobel Holding Ltd. acquired a new stake in Ultragenyx Pharmaceutical, purchasing 10,464 shares valued at approximately $380,000 during the 2nd quarter.
  • Ultragenyx Pharmaceutical's stock has seen a 1% decline recently, with current trading at $31.69, and has a market capitalization of $3.05 billion.
  • Despite reporting a negative earnings per share of ($1.17), Ultragenyx's revenue rose by 13.2% year-over-year, totaling $166.50 million for the last quarter.
  • Interested in Ultragenyx Pharmaceutical? Here are five stocks we like better.

Vontobel Holding Ltd. bought a new stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 10,464 shares of the biopharmaceutical company's stock, valued at approximately $380,000.

Other large investors have also recently bought and sold shares of the company. Fred Alger Management LLC increased its holdings in Ultragenyx Pharmaceutical by 12.5% in the first quarter. Fred Alger Management LLC now owns 524,637 shares of the biopharmaceutical company's stock valued at $18,997,000 after buying an additional 58,372 shares during the last quarter. Wealth Enhancement Advisory Services LLC purchased a new position in Ultragenyx Pharmaceutical in the second quarter valued at $353,000. Assenagon Asset Management S.A. increased its holdings in Ultragenyx Pharmaceutical by 439.0% in the second quarter. Assenagon Asset Management S.A. now owns 1,163,755 shares of the biopharmaceutical company's stock valued at $42,314,000 after buying an additional 947,865 shares during the last quarter. Millennium Management LLC increased its holdings in Ultragenyx Pharmaceutical by 2.2% in the first quarter. Millennium Management LLC now owns 712,393 shares of the biopharmaceutical company's stock valued at $25,796,000 after buying an additional 15,157 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in Ultragenyx Pharmaceutical by 18.0% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,652 shares of the biopharmaceutical company's stock valued at $133,000 after buying an additional 557 shares during the last quarter. Hedge funds and other institutional investors own 97.67% of the company's stock.

Ultragenyx Pharmaceutical Stock Down 1.0%

NASDAQ RARE opened at $31.69 on Wednesday. Ultragenyx Pharmaceutical Inc. has a 52-week low of $25.81 and a 52-week high of $57.99. The business's 50-day moving average price is $29.88 and its 200 day moving average price is $32.93. The firm has a market cap of $3.05 billion, a P/E ratio of -5.73 and a beta of 0.21.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.27) by $0.10. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%.The firm had revenue of $166.50 million for the quarter, compared to analyst estimates of $161.37 million. During the same quarter last year, the company posted ($1.52) earnings per share. The business's revenue was up 13.2% on a year-over-year basis. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. As a group, analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

Analyst Ratings Changes

Several research firms recently commented on RARE. Guggenheim reissued a "buy" rating and issued a $64.00 target price on shares of Ultragenyx Pharmaceutical in a report on Friday, June 20th. Morgan Stanley dropped their price objective on Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating on the stock in a report on Monday, July 14th. HC Wainwright reaffirmed a "buy" rating and set a $80.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Tuesday, September 9th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Ultragenyx Pharmaceutical in a report on Wednesday, October 8th. Finally, Wedbush dropped their price objective on Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a "neutral" rating on the stock in a report on Monday, July 14th. Eleven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Ultragenyx Pharmaceutical has an average rating of "Moderate Buy" and an average price target of $81.50.

Check Out Our Latest Research Report on RARE

Insider Transactions at Ultragenyx Pharmaceutical

In related news, CFO Howard Horn sold 7,942 shares of the firm's stock in a transaction dated Monday, October 13th. The shares were sold at an average price of $31.51, for a total value of $250,252.42. Following the completion of the sale, the chief financial officer owned 98,227 shares in the company, valued at $3,095,132.77. This trade represents a 7.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Karah Herdman Parschauer sold 2,450 shares of the firm's stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $31.17, for a total transaction of $76,366.50. Following the completion of the sale, the executive vice president owned 73,271 shares of the company's stock, valued at approximately $2,283,857.07. The trade was a 3.24% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 10,456 shares of company stock valued at $328,486. 5.50% of the stock is owned by insiders.

Ultragenyx Pharmaceutical Profile

(Free Report)

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

Recommended Stories

Institutional Ownership by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Ultragenyx Pharmaceutical Right Now?

Before you consider Ultragenyx Pharmaceutical, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ultragenyx Pharmaceutical wasn't on the list.

While Ultragenyx Pharmaceutical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report
Like this article? Share it with a colleague.